Atid-219 Access

The FDA’s will likely treat ATID‑219 as a complex biologic‑device combination . The agency’s recent guidance on AI‑assisted drug discovery and gene‑editing therapeutics suggests a multi‑track review:

Assuming a annual sales trajectory in the first three years post‑approval (given the high unmet need in PDAC and TNBC), ATID‑219 could generate $1–2 B in cumulative revenue within a decade. The platform nature —allowing rapid re‑targeting—positions it as a license‑generating asset for partner companies. atid-219